Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.51

-2.4%

Dec 23 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (11926)	6/5/2004 2:05:11 PM
From: Miljenko Zuanic	of 52153

<<milestone and royalty depend on what the biotech wants to do>> Yes, fully agree. Excellent explanation. Generally I take milestone as 20% of the projected pick annual sale, but there are many factors that can change this 20%. Royalty is the biggest one. One need to calculate (project) drug economic and how much of the profit is going to bios relative to pharma, and again relative to investment of the licensor. Miljenko PS: PLiva make sound investment in IDEV, imo.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next